ALKS vs BK · P/E 14, rev $1.56B vs P/E 17, rev $20.08B
Alkermes Plc (ALKS) versus The Bank of New York Mellon Corporation (BK) — a side-by-side from cached financials, not a winner call.
Alkermes Plc (ALKS) is a drug manufacturers - specialty & generic company listed on US.
The Bank of New York Mellon Corporation (BK) is a banks - diversified company listed on US.
Latest reported ALKS revenue for 2024-12-31 was $1.56B. Net income was $367.1M. Revenue was down 6.4% from 2023-12-31 to 2024-12-31. ALKS currently screens at market cap $4.78B and trailing P/E 13.8.
Latest reported BK revenue for 2025-12-31 was $20.08B. Net income was $5.55B. Revenue was up 7.8% from 2024-12-31 to 2025-12-31. BK currently screens at market cap $94.14B and trailing P/E 17.0.
ALKS currently screens at market cap $4.78B and trailing P/E 13.8. BK currently screens at market cap $94.14B and trailing P/E 17.0.
Not investment advice. Open the ALKS and BK stock pages for the full models.
Not investment advice.